Bellevue Asset Management’s Heron Therapeutics HRTX Stock Holding History

Bellevue Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-165	Closed	-$2K	–	550
2021 Q4	$2K	Sell	165 -14	-8%	-$143	﹤0.01%	495
2021 Q3	$2K	Hold	179	–	–	﹤0.01%	519
2021 Q2	$3K	Sell	179 -21	-11%	-$334	﹤0.01%	453
2021 Q1	$3K	Sell	200 -21	-10%	-$374	﹤0.01%	512
2020 Q4	$4K	Sell	221 -51	-19%	-$886	﹤0.01%	464
2020 Q3	$4K	Hold	272	–	–	﹤0.01%	426
2020 Q2	$4K	Hold	272	–	–	﹤0.01%	425
2020 Q1	$4K	Buy	+272	New	+$5.11K	﹤0.01%	414

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Bellevue Asset Management's HRTX Position: Q1 2022 in Review

Bellevue Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 165 shares — an estimated $2K sold.

Bellevue Asset Management first reported a position in HRTX in Q1 2020 and held it in 8 quarters. The position peaked at $4K in Q4 2020. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

Bellevue Asset Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
Bellevue Asset Management sold 165 Heron Therapeutics shares in Q1 2022, an estimated $2K.
Bellevue Asset Management first reported a position in Heron Therapeutics in Q1 2020 and held it in 8 quarters.
Bellevue Asset Management's Heron Therapeutics position peaked at $4K in Q4 2020.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Bellevue Asset Management's 13F filing for Q1 2022, filed 11 May 2022.